Topic: Coronavirus

Latest content

Breakthrough in TRIPS covid waiver negotiations – here’s what you need to know

There are reports of a compromise deal agreeed by the US, EU, India and South Africa, but no official confirmation

16 March 2022

Vaccine hub leader welcomes new Moderna patent pledge, but calls for collaboration

Petro Terblanche speaks to IAM about the mRNA innovator’s expanded IP commitment

14 March 2022

Platform technology owners demand a chunk of Moderna’s covid-19 revenues

Arbutus Biopharma and Genevant Sciences have filed suit against the vaccine innovator

07 March 2022

Russian Supreme Court rejects Gilead’s decree challenge

In a closely watched case, the Supreme Court has upheld the Civil Code’s prioritising of people’s lives and health during the covid-19 pandemic, over profits lost to patent owners

23 February 2022

BioNTech confirms it will not enforce covid 19 patents – at least for now

The German biotech company becomes the second mRNA vaccine maker to say it will not take legal action during pandemic

21 February 2022

Why the proposed covid TRIPs waiver is a solution in search of a problem

Rigorous correlation analysis makes the case that IP rights are not the barrier to vaccine and treatment access that advocates claim, argues David Torstensson

16 February 2022

Lack of mRNA tech transfer “a blessing in disguise” for WHO vaccine team, says Afrigen boss

Petro Terblanche tells IAM about the IP issues surrounding her team’s new replica of Moderna’s covid-19 vaccine

10 February 2022

WHO’s vaccine successes show significance of Moderna covid IP pledge

African tech transfer hub is making fast progress in replicating the approved mRNA jab

18 January 2022

The challenges keeping patent owners awake at night as they look ahead to 2022

IAM’s Global Leaders provide the inside scoop on some of the biggest difficulties they are helping their clients navigate, from patent eligibility to labour shortages

13 December 2021

Germany’s new government is the last hope for covid IP waiver advocates

A post-Merkel change of approach by the country’s recently agreed traffic light coalition government could change the momentum of TRIPS suspension talks – but don’t bet on it

07 December 2021

Get unlimited access to all IAM content